Insulin Regulation of Lipolysis and Lipolysis Proteins

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Men and Women between the ages of 18 and 55.

• Women will be premenopausal

• Non obese adults BMI between 18-25

• Obese BMI 30-38

Exclusion Criteria, Pioglitazone package insert of contraindications for use:

• Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.

• Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.